OGN
Organon & Co.Company Information
- Company Name
- Organon & Co.
- CIK
- CIK0001821825
- Category
- Large accelerated filer
- Ticker: Exchange
- OGN: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- OGN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-06
- Last sale
- 2026-08-05
- Shares purchased (TTM)
- 91,848.37
- Shares sold (TTM)
- 41,209.37
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 216,012,512
- Shares outstanding
- 262,611,000
- Ownership
- 82.26%
Earnings Market Reaction
- Filing date
- 2026-07-31
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1,132 | 1,116 | 574 | 672 | 599 | 547 | 675 | 763 | 704 | 575 | 693 | 414 | ||||||
| Accounts Receivable Net Current | 1,492 | 1,384 | 1,331 | 1,484 | 1,484 | 1,457 | 1,358 | 1,685 | 1,617 | 1,547 | 1,744 | 1,648 | ||||||
| Inventory Net | 1,351 | 1,373 | 1,406 | 1,488 | 1,454 | 1,362 | 1,321 | 1,383 | 1,287 | 1,263 | 1,315 | 1,186 | ||||||
| Other Assets Current | 1,136 | 1,059 | 1,033 | 1,056 | 1,081 | 1,005 | 994 | 925 | 901 | 811 | 756 | 802 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 8 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 5,111 | 4,932 | 4,352 | 4,700 | 4,618 | 4,371 | 4,348 | 4,756 | 4,509 | 4,196 | 4,508 | 4,050 | ||||||
| Property Plant And Equipment Net | 1,281 | 1,279 | 1,303 | 1,290 | 1,266 | 1,197 | 1,168 | 1,204 | 1,162 | 1,180 | 1,183 | 1,096 | ||||||
| Goodwill | 4,153 | 4,153 | 4,153 | 4,680 | 4,680 | 4,680 | 4,680 | 4,603 | 4,603 | 4,603 | 4,603 | 4,603 | ||||||
| Finite Lived Intangible Assets Net | 1,112 | 1,099 | 1,130 | 1,340 | 1,362 | 1,417 | 1,414 | 763 | 684 | 718 | 533 | 561 | ||||||
| Deferred Income Taxes And Other Assets Noncurrent | 1,521 | 1,533 | 1,539 | 1,542 | 1,574 | 1,491 | 1,491 | 1,426 | 1,196 | 1,194 | 1,231 | 702 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | 0 | 0 | 390 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets | 13,178 | 12,996 | 12,867 | 13,552 | 13,500 | 13,156 | 13,101 | 12,752 | 12,154 | 11,891 | 12,058 | 11,012 | ||||||
| Long Term Debt Current | - | - | - | - | - | 20 | 20 | 10 | 9 | 9 | 9 | 8 | ||||||
Liabilities Current | ||||||||||||||||||
| Debt Current | 74 | 16 | 16 | 45 | 115 | - | 20 | - | - | - | - | - | ||||||
| Accounts Payable Current | 1,051 | 983 | 952 | 1,074 | 1,067 | 1,006 | 1,153 | 1,092 | 1,243 | 955 | 1,314 | 1,067 | ||||||
| Accrued Income Taxes Current | 84 | 77 | 85 | 116 | 194 | 176 | 134 | 230 | 201 | 196 | 206 | 161 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 2 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 2,616 | 2,500 | 2,390 | 2,679 | 2,796 | 2,615 | 2,718 | 2,790 | 2,755 | 2,545 | 2,918 | 2,491 | ||||||
| Long Term Debt Noncurrent | 8,479 | 8,553 | 8,628 | 8,783 | 8,781 | 8,936 | 8,860 | 8,739 | 8,647 | 8,705 | 8,751 | 8,646 | ||||||
| Deferred Income Tax Liabilities Net | 51 | 56 | 57 | 62 | 69 | 69 | 74 | 56 | 60 | 44 | 47 | 43 | ||||||
| Other Liabilities Noncurrent | 1,026 | 984 | 1,008 | 1,122 | 1,121 | 994 | 977 | 674 | 548 | 549 | 412 | 421 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | 0 | 0 | 32 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 12,172 | 12,093 | 12,115 | 12,646 | 12,767 | 12,614 | 12,629 | 12,259 | 12,010 | 11,843 | 12,128 | 11,601 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Additional Paid In Capital Common Stock | 199 | 186 | 167 | 159 | 139 | 130 | 108 | 86 | 63 | 49 | 25 | - | ||||||
| Retained Earnings Accumulated Deficit | 1,352 | 1,253 | 1,109 | 1,318 | 1,163 | 1,026 | 1,010 | 975 | 690 | 573 | 443 | -16 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -548 | -539 | -527 | -574 | -572 | -617 | -649 | -571 | -612 | -577 | -541 | -576 | ||||||
| Stockholders Equity | 1,006 | 903 | 752 | 906 | 733 | 542 | 472 | 493 | 144 | 48 | -70 | -589 | ||||||
| Liabilities And Stockholders Equity | 13,178 | 12,996 | 12,867 | 13,552 | 13,500 | 13,156 | 13,101 | 12,752 | 12,154 | 11,891 | 12,058 | 11,012 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 13 | 14 | 12 | 12 | 12 | 12 | 14 | 13 | 10 | 11 | 9 | 9 | ||||||
| Inventory Noncurrent | 273 | 252 | 236 | 247 | 240 | 207 | 215 | 130 | 113 | 101 | 110 | 95 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 263 | 263 | 260 | 260 | 260 | 258 | 258 | 258 | 257 | 256 | 256 | 256 | ||||||
| Shares Outstanding | 263 | 263 | 260 | 260 | 260 | 258 | 258 | 258 | 257 | 256 | 256 | 256 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOrganon & Co. (OGN) — SEC Financial Statements & Analysis
Organon & Co. (OGN) is a pharmaceutical preparations company. Organon & Co. trades on NYSE as: OGN. Organon & Co. (OGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31. Based on that filing, Organon & Co. carries a market cap of $3.55B, a P/E ratio of 16.99x, a P/B ratio of 3.53x, a P/S ratio of 0.58x, an enterprise value of $10.97B, and an EV/EBITDA multiple of 9.81x. On profitability, it posts a gross margin of 52.68%, an operating margin of 8.01%, a net margin of 3.41%, a Return on Equity (ROE) of 24.04%, a Return on Assets (ROA) of 1.57%, and a Return on Invested Capital (ROIC) of 4.61%. Per share, it reports EPS of $0.80, diluted EPS of $0.77, free cash flow per share of $2.16, and a dividend per share of $0.07. Over the trailing year, it posted revenue growth of -2.45% year-over-year, net income growth of -70.14% year-over-year, and EPS growth of -70.45% year-over-year. On the balance sheet, it maintains a current ratio of 1.95x, a quick ratio of 1.44x, working capital of $2.50B, a debt-to-equity ratio of 12.10x, a debt ratio of 0.92, an interest coverage ratio of 2.05x, free cash flow of $567.00M (TTM), and net debt of $7.42B. Figures sourced from SEC EDGAR.
- Market Cap
- $3.55B
- P/E TTM
- 16.99x
- EPS TTM
- $0.80
- P/B TTM
- 3.53x
- ROE TTM
- 24.04%
- ROA TTM
- 1.57%
- Debt To Equity
- 12.10x
- Free Cash Flow TTM
- $567.00M
- Net Revenue TTM Growth 1Y
- -2.45%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Organon & Co. in?
Organon & Co. (OGN) operates in the Pharmaceutical Preparations industry.
What exchange does OGN trade on?
Organon & Co. (OGN) trades on the NYSE.
When was Organon & Co. (OGN)'s most recent SEC filing?
Organon & Co. (OGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31.
What is OGN's market cap?
Organon & Co. (OGN) has a market capitalization of $3.55B as of 2026-06-30.
What is OGN's P/E ratio?
Organon & Co. (OGN)'s trailing twelve month P/E ratio is 16.99x as of 2026-06-30.
What is OGN's EPS (earnings per share)?
Organon & Co. (OGN)'s trailing twelve month EPS is $0.80 as of 2026-06-30.
What is OGN's ROE (return on equity)?
Organon & Co. (OGN)'s trailing twelve month Return on Equity (ROE) is 24.04% as of 2026-06-30.
What is OGN's ROA (return on assets)?
Organon & Co. (OGN)'s trailing twelve month Return on Assets (ROA) is 1.57% as of 2026-06-30.
What is OGN's ROIC (return on invested capital)?
Organon & Co. (OGN)'s trailing twelve month Return on Invested Capital (ROIC) is 4.61% as of 2026-06-30.
What is OGN's EV/EBITDA?
Organon & Co. (OGN)'s trailing twelve month EV/EBITDA is 9.81x as of 2026-06-30.